On this page
Referral and warning signs
When to refer
Refer ALL children with signs of precocious puberty (before age 8 in girls, 9 in boys) to a Paediatric Endocrinologist/Specialist for: Diagnosis confirmation (GnRH stim test, MRI). Identification of underlying cause. Initiation and management of GnRH agonist therapy.
Red flags
- Onset of puberty before age 8 (girls) / 9 (boys)
- Rapidly progressing pubertal signs
- Accelerated growth velocity
- Neurological symptoms (headache, visual changes, seizures)
- Signs suggesting peripheral precocity (e.g., virilization without testicular enlargement in boy, isolated breast development with vaginal bleeding in girl)
Signs and symptoms
- Girls (<8 years): Premature breast development (thelarche), Pubic/axillary hair growth (pubarche/adrenarche), Onset of menstruation (menarche), Accelerated growth velocity, Advanced bone age.
- Boys (<9 years): Testicular enlargement (>4ml volume or >2.5cm length), Penile enlargement, Pubic/axillary/facial hair growth, Deepening voice, Acne, Accelerated growth velocity, Advanced bone age.
- Sequence of pubertal events is typically normal, just occurs early.
Risk factors
- Idiopathic (most common cause, especially in girls).
- CNS abnormalities (Secondary CPP):
- - Brain tumours (hypothalamic hamartoma, glioma, astrocytoma).
- - CNS infections (meningitis, encephalitis).
- - Brain malformations (hydrocephalus, arachnoid cysts).
- - Cranial irradiation.
- - Head trauma.
- Previous exposure to exogenous sex steroids.
- Genetic factors (rare familial cases).
Diagnosis
Clinical assessment
Diagnosis based on appearance of secondary sexual characteristics before age 8 (girls) or 9 (boys). Assess tempo of puberty, growth velocity. Detailed history (onset, sequence, CNS symptoms, exposures). Physical exam (Tanner staging, height/weight, neurological exam). Differentiate from benign variants (premature thelarche, premature adrenarche) and gonadotropin-independent precocious puberty (peripheral causes).
Investigations
- Bone Age Assessment (X-ray of left hand/wrist): Typically advanced compared to chronological age.
- Baseline Gonadotropin levels (LH, FSH): May be in pubertal range, but often low/prepubertal basally.
- GnRH Stimulation Test: Confirmatory test for CPP. Measures LH/FSH response after GnRH agonist administration. A pubertal LH response confirms central activation of HPG axis (specialist test).
- Sex Steroid levels (Estradiol in girls, Testosterone in boys): May be elevated into pubertal range.
- Pelvic Ultrasound (Girls): Assess ovarian/uterine size and morphology (pubertal changes).
- Brain MRI: Essential to rule out CNS lesions (tumours, malformations) as the cause, especially in boys and very young girls (<6 years).
- Genetic testing (rare familial cases).
Diagnostic criteria
Clinical signs of puberty before age 8 (girls) / 9 (boys) + Advanced bone age + Confirmed pubertal response on GnRH stimulation test.
Management
Non-pharmacological management
- Treat Underlying CNS Cause (if identified): e.g., surgery/radiation for tumour.
- Psychosocial Support: For child and family to address emotional/social challenges of early puberty.
- Monitor growth and pubertal development.
Pharmacological treatment
- Goal: Suppress puberty to allow for further growth (preserve adult height potential) and align psychosocial development.
- GnRH Agonist Therapy: Treatment of choice. Suppresses pituitary gonadotropin release, halting pubertal progression and slowing bone age advancement.
- - Leuprolide acetate depot suspension: Administered IM monthly (e.g., 7.5mg) or every 3 months.
- - Histrelin implant: Long-acting subdermal implant (annual).
- - Treatment typically continued until a more appropriate age for puberty (e.g., 11-12 years).
- - Requires specialist initiation and monitoring.
Monitoring
Monitor growth velocity, pubertal stage (Tanner), bone age progression (e.g., every 6-12 months). Monitor LH/FSH/sex steroid levels to confirm suppression on GnRH agonist therapy. Monitor for side effects of treatment (local reactions, rare headaches).
Complications
- Short adult stature (due to premature fusion of growth plates).
- Psychosocial difficulties (feeling different from peers, potential for early sexualisation/risk behaviours).
- Emotional distress.
- Complications related to underlying CNS lesion if present.
Prevention
- Not generally preventable, but early detection and treatment of CNS lesions can address secondary CPP.
Patient education
- (To parents/child) Explain CPP and its cause (if known).
- Rationale for treatment (preserve height, psychosocial adjustment).
- How GnRH agonist therapy works (suppresses puberty temporarily).
- Administration schedule (injections/implant).
- Need for regular monitoring.
- Expected outcomes and when treatment might stop.
- Addressing psychosocial concerns.
Uganda-specific notes
Recognition may be delayed. Access to specialist Paediatric Endocrine care, hormonal testing (esp. GnRH stimulation), Brain MRI, and GnRH agonist therapy is extremely limited.
References
- Uganda Clinical Guidelines (UCG) 2023
Chapter 8, Section 8.1.8